Wednesday 21 March 2012 |
Morning |
09:00 |
Registration and placing of posters |
10:30 |
Welcome |
10:40 |
Opening Talk
Hendrik Fuchs
(Charité, Berlin, Germany)
Targeted therapy — past, present, and future |
Chair: Hendrik Fuchs |
11:00 |
Luzie Fabisch Memorial Lecture
 Daniel A. Vallera
(University of Minnesota Cancer Center, Minneapolis, MN, USA)
Genetic engineering new targeting agents to cancer cells and cancer stem cells |
11:50 |
Philipp Wolf
(University Hospital Freiburg, Germany)
In vitro and in vivo efficacy of an anti-PSMA immunotoxin against prostate cancer |
12:25 |
Jeannick P.A. Cizeau
(Viventia Biotechnologies Inc., Winnipeg, Canada)
DeBouganin: A de-immunized toxin payload and its applications in oncology |
13:00 |
Coffee, snack & posters |
|
|
Wednesday 21 March 2012 |
Afternoon |
Chair: Arthur E. Frankel |
14:15 |
Stefan Gattenlöhner
(University Hospital Gießen and Marburg (UKGM) GmbH, Germany)
Targeting rhabdomyosarcomas with a novel immunotoxin directed against the fetal form of the acetylcholine receptor |
14:35 |
Luis A. Pardo
(Max-Planck-Institute of Experimental Medicine, Göttingen, Germany)
Efficacy of bifunctional TRAIL-KV10.1 potassium channel antibody in xenograft models |
14:50 |
Wijnand Helfrich
(Groningen University, The Netherlands)
Cell surface delivery of TRAIL strongly augments the tumoricidal activity of T cells |
15:25 |
Winfried Wels
(Georg-Speyer-Haus, Frankfurt, Germany)
Targeted induction of tumor cell death by gene-modified killer cells |
16:00 |
Claudia De Lorenzo
(University of Napoli, Italy)
First and second generation human anti-ErbB2 immunoagents |
16:35 |
Coffee break |
Chair: Stefan Dübel |
17:00 |
Agnes Banaszek
(Universitätsklinikum Würzburg, Germany)
Dual antigen-restricted complementation of a trispecific antibody construct for targeted immunotherapy of blood cancer |
17:15 |
Hossein Panjideh
(Max Delbrück Centrum für Molekulare Medizin, Berlin, Germany)
Monitoring of therapeutic efficiacy and immune responses using bispecific antibodies in mouse leukemia/lymphoma models |
17:35 |
Uwe Zangemeister-Wittke
(University of Bern & University of Zurich, Switzerland)
Tumor targeting with DARPin-based toxin conjugates |
18:10 |
Georg H. Fey
(University of Erlangen-Nuremberg, Germany)
Single chain triplebodies for the elimination of leukemic cells
|
18:45 |
Nicole Schellmann
(Charité, Berlin, Germany)
Targeting of solid tumors by antibody-directed enzyme prodrug therapies |
19:00 |
Get together & posters |
21:30 |
Free time to explore Berlin by night |
|
| |
|
|
Thursday 22 March 2012 |
Morning |
Chair: Daniel A. Vallera |
08:30 |
Rodolfo Ippoliti
(University of L'Aquila, Italy)
Exploring new targets and delivery systems against cancer cells |
09:10 |
Stefan Dübel
(Technical University Braunschweig, Germany)
Recombinant human antibodies for target identification |
09:45 |
Michael G. Rosenblum
(University of Texas, Houston, TX, USA)
Fusion constructs targeting metastatic spread, skeletal tumors and tumor vasculature – a multifaceted approach with one molecule |
10:20 |
Pål K. Selbo
(Norwegian Radium Hospital, Oslo and PCI Biotech AS, Lysaker, Norway)
Photochemical internalization – an innovative tool to improve targeted tumor therapies |
10:45 |
Coffee break |
Chair: Yvonne Andersson |
11:15 |
Roland Kontermann
(University of Stuttgart, Germany)
Half-life extension strategies to improve targeted delivery of antibodies |
11:50 |
Felix Kratz
(Tumor Biology Center, Freiburg, Germany)
Serum proteins as carriers for drugs, toxins and antibodies – from preclinical to clinical application |
12:25 |
David J. Fitzgerald
(NIH, National Cancer Institute, Bethesda, MD, USA)
Combination treatments of cancer with Immunotoxins and Bcl-2 antagonists |
13:00 |
Lunch & posters |
|
|
Thursday 22 March 2012 |
Afternoon |
Chair: Winfried Wels |
14:15 |
Klaus Pfizenmaier
(University of Stuttgart, Germany)
Superior anti-tumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity |
14:50 |
Andrew Thorburn
(University of Colorado Denver, Aurora, CO, USA)
Manipulating apoptosis and autophagy to improve targeted toxin therapy |
15:25 |
Stefan Barth
(Fraunhofer-Institute for Molecular Biology and Applied Ecology, Aachen, Germany)
Recombinant cytolytic fusion proteins for the treatment of CD64-positive diseases |
16:00 |
Arthur E. Frankel
(Cancer Research Institute of Scott & White, Temple, TX, USA)
Targeting cancer amino acid auxotrophy with pegylated recombinant human amino acid hydrolases |
16:35 |
Mini refreshment |
16:50 |
Bus transfer to the Spree |
17:30 |
Boat tour including dinner |
21:30 |
Bus transfer to the hotels |
|
| |
|
|
Friday 23 March 2012 |
Morning |
Chair: Nicole Schellmann |
08:30 |
Diana Bachran
(Charité, Berlin, Germany)
Enhancers of endosomal escape for improved targeted drug delivery |
09:10 |
David Flavell
(Southampton General Hospital, UK)
Exploring ways of improving the therapeutic window of immunotoxins |
09:45 |
Jennifer E. Adcott
(Southampton General Hospital, UK)
The effects of Gypsophila saponins on the internalization of an anti-CD22 immunotoxin |
10:00 |
Emma Dearing
(Southampton General Hospital, UK)
Augmentative activities of saponin species derived from various natural sources on immunotoxin cytotoxicity for human leukemia and lymphoma cell lines |
10:15 |
Mayank Thakur
(Charité, Berlin, Germany)
Isolation techniques of saponins and their in vivo evaluation as enhancers in targeted tumor therapy |
10:30 |
Coffee break |
Chair: David J. Fitzgerald |
11:00 |
Matthias Peipp
(Christian-Albrechts-University Kiel, Germany)
Human kappa light chain targeted Pseudomonas exotoxin A – Identifying human antibodies with favorable characteristics for antibody-drug conjugate development |
11:15 |
Yvonne Andersson
(Cancer Research, Oslo, Norway)
Immunotoxins in targeted cancer therapy, from bench to bedside |
11:50 |
Uwe Haberkorn
(University Hospital Heidelberg & German Cancer Research Center, Heidelberg, Germany)
Endoradiotherapy with peptides – clinical application and new developments |
12:25 |
Michaela Arndt
(National Center for Tumor Diseases, Heidelberg, Germany)
Immunotherapy of nucleoside analog resistant Herpes simplex virus infections after allogenic stem-cell transplantation |
13:00 |
Lunch |
|
|
Friday 23 March 2012 |
Afternoon |
Chair: Stefan Barth |
14:00 |
Ralph J. Abi-Habib
(Lebanese American University, 1102 2801 Beirut, Lebanon)
Human recombinant arginase I (Co)-PEG5000 is selectively cytotxic to human acute myeloid leukemia (AML) cell lines |
14:20 |
Thomas Schirrmann
(Technical University Braunschweig, 38106 Braunschweig, Germany)
Antibodies and antibody RNase fusion proteins targeting CD30+ lymphoma |
14:45 |
Christopher Bachran
(NIH, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA)
Ubiquitin-anthrax toxin fusion proteins for the modulation of toxin release and cytotoxicity of tumor-targeted anthrax toxins |
15:10 |
Shihui Liu
(NIH, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA)
Treating solid tumors with protease-activated anthrax toxin |
15:45 |
Alexander Weng
(Charité, Berlin, Germany)
Therapeutic potential of a combinatorial anti-tumor therapy: role of the toxin moiety |
16:00 |
Suzanne E. Holmes
(Southampton General Hospital, UK)
Mechanistic studies of the augmentative effect of Gypsophila saponins on saporin-based immunotoxins |
16:15 |
Concluding remarks (Hendrik Fuchs) |
16:45 |
Bus transfer to the Television Tower |
17:45 |
Sunset meeting dinner above the buildings of Berlin |
22:15 |
Bus transfer to the hotels |
|
.